Last reviewed · How we verify

NCT06851351: RESPIPWS

Respiratory Restriction in Prader-Willi Syndrome

Completed Last updated 28 February 2025
What this trial tests

trial testing Spirometry and optoelectronic plethysmography in Prader-Willi Syndrome in 30 participants. Completed in 5 July 2024.

Timeline
16 January 2024
Primary endpoint
5 July 2024
5 July 2024

Quick facts

Lead sponsorIstituto Auxologico Italiano
StatusCompleted
Study typeOBSERVATIONAL
Enrollment30
Start date16 January 2024
Primary completion5 July 2024
Estimated completion5 July 2024
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Istituto Auxologico Italiano — full company profile →

Who can join

Adults 20 to 50, any sex, with Prader-Willi Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this study is therefore to evaluate the impact of Prader Willi Syndrome (PWS) on lung and thoracoabdominal volumes, respiratory muscle strength and awake ventilatory pattern, and to quantify and localize the PWS-induced respiratory restriction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Prader-Willi Syndrome

Currently open trials in the same condition.

Other Istituto Auxologico Italiano trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06851351.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing